Polatuzumab Vedotin OverviewPolatuzumab vedotin (INN; brand name Polivy; development codes DCDS4501A and RG7596) is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab. The drug was developed by Genentech and Roche. Polatuzumab vedotin contains a humanized monoclo...
Read more Polatuzumab Vedotin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Polatuzumab_vedotin
Recent Polatuzumab Vedotin Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 140mg
Other drugs which contain Polatuzumab Vedotin or a similar ingredient: (1 result)
- POLIVY Polatuzumab Vedotin-piiq